Published in N Engl J Med on April 27, 2008
Safety Study in Subjects With Leber Congenital Amaurosis | NCT00516477
Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis | NCT00999609
An Open Label Clinical Trial of Retinal Gene Therapy for Choroideremia | NCT02077361
Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell (2009) 11.10
Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther (2008) 8.83
Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci U S A (2008) 7.16
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet (2009) 6.71
In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature (2011) 4.81
Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med (2010) 4.28
Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. Lancet (2014) 4.24
Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther (2009) 3.93
Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature (2011) 3.80
Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol (2011) 3.79
AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood (2009) 3.65
Photoreceptor degeneration: genetic and mechanistic dissection of a complex trait. Nat Rev Genet (2010) 3.20
Improvement and decline in vision with gene therapy in childhood blindness. N Engl J Med (2015) 3.16
Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum Gene Ther (2009) 3.07
CEP290 tethers flagellar transition zone microtubules to the membrane and regulates flagellar protein content. J Cell Biol (2010) 3.07
High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol Ther (2008) 2.93
AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med (2012) 2.87
Effect of genome size on AAV vector packaging. Mol Ther (2009) 2.77
Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc Natl Acad Sci U S A (2013) 2.71
Long-term effect of gene therapy on Leber's congenital amaurosis. N Engl J Med (2015) 2.68
Vision 1 year after gene therapy for Leber's congenital amaurosis. N Engl J Med (2009) 2.57
The AAV vector toolkit: poised at the clinical crossroads. Mol Ther (2012) 2.53
Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale. Hum Gene Ther (2010) 2.51
Assessing the potential for AAV vector genotoxicity in a murine model. Blood (2010) 2.48
Gene therapy for red-green colour blindness in adult primates. Nature (2009) 2.44
In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration. Nature (2016) 2.37
Next-generation genetic testing for retinitis pigmentosa. Hum Mutat (2012) 2.30
Good manufacturing practice production of self-complementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trial. Hum Gene Ther (2011) 2.29
In vivo autofluorescence imaging of the human and macaque retinal pigment epithelial cell mosaic. Invest Ophthalmol Vis Sci (2008) 2.19
Efficient serotype-dependent release of functional vector into the culture medium during adeno-associated virus manufacturing. Hum Gene Ther (2010) 2.19
Gene therapy rescues cone function in congenital achromatopsia. Hum Mol Genet (2010) 2.18
Engineering adeno-associated viruses for clinical gene therapy. Nat Rev Genet (2014) 2.16
Lighting a candle in the dark: advances in genetics and gene therapy of recessive retinal dystrophies. J Clin Invest (2010) 2.13
Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood (2013) 2.09
Spectral domain optical coherence tomography in mouse models of retinal degeneration. Invest Ophthalmol Vis Sci (2009) 2.08
The pleiotropic effects of natural AAV infections on liver-directed gene transfer in macaques. Mol Ther (2009) 2.08
Photoreceptor layer topography in children with leber congenital amaurosis caused by RPE65 mutations. Invest Ophthalmol Vis Sci (2008) 2.06
Progress and prospects: immune responses to viral vectors. Gene Ther (2009) 2.05
Treatment of macular degeneration using embryonic stem cell-derived retinal pigment epithelium: preliminary results in Asian patients. Stem Cell Reports (2015) 1.90
The retinal pigment epithelium in health and disease. Curr Mol Med (2010) 1.87
NMNAT1 mutations cause Leber congenital amaurosis. Nat Genet (2012) 1.86
Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2. Ophthalmology (2013) 1.85
Retinitis pigmentosa: genes and disease mechanisms. Curr Genomics (2011) 1.85
Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy. Prog Retin Eye Res (2010) 1.81
High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol Ther (2010) 1.78
Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther (2010) 1.77
Gene therapy for retinitis pigmentosa and Leber congenital amaurosis caused by defects in AIPL1: effective rescue of mouse models of partial and complete Aipl1 deficiency using AAV2/2 and AAV2/8 vectors. Hum Mol Genet (2009) 1.76
Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous. Mol Ther (2009) 1.73
Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors. Hum Gene Ther (2011) 1.71
Characterization of genome integrity for oversized recombinant AAV vector. Mol Ther (2009) 1.71
A comprehensive review of retinal gene therapy. Mol Ther (2013) 1.70
DNA shuffling of adeno-associated virus yields functionally diverse viral progeny. Mol Ther (2008) 1.70
ABCA4 disease progression and a proposed strategy for gene therapy. Hum Mol Genet (2008) 1.69
Long-term preservation of cones and improvement in visual function following gene therapy in a mouse model of leber congenital amaurosis caused by guanylate cyclase-1 deficiency. Hum Gene Ther (2011) 1.68
The role of the photoreceptor ABC transporter ABCA4 in lipid transport and Stargardt macular degeneration. Biochim Biophys Acta (2009) 1.66
Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer. EMBO Mol Med (2012) 1.66
X-linked juvenile retinoschisis: clinical diagnosis, genetic analysis, and molecular mechanisms. Prog Retin Eye Res (2012) 1.66
Gene therapies advance towards finish line. Nat Rev Drug Discov (2011) 1.64
Evidence for the failure of adeno-associated virus serotype 5 to package a viral genome > or = 8.2 kb. Mol Ther (2009) 1.64
AAV-mediated gene therapy for choroideremia: preclinical studies in personalized models. PLoS One (2013) 1.62
The AAV9 receptor and its modification to improve in vivo lung gene transfer in mice. J Clin Invest (2011) 1.58
Molecular evolution of adeno-associated virus for enhanced glial gene delivery. Mol Ther (2009) 1.57
Intravitreal delivery of AAV8 retinoschisin results in cell type-specific gene expression and retinal rescue in the Rs1-KO mouse. Gene Ther (2009) 1.56
Overcoming preexisting humoral immunity to AAV using capsid decoys. Sci Transl Med (2013) 1.56
Defining the residual vision in leber congenital amaurosis caused by RPE65 mutations. Invest Ophthalmol Vis Sci (2008) 1.54
Functional cone rescue by RdCVF protein in a dominant model of retinitis pigmentosa. Mol Ther (2009) 1.53
The human visual cortex responds to gene therapy-mediated recovery of retinal function. J Clin Invest (2011) 1.52
Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma. Nat Rev Drug Discov (2012) 1.52
Characterization of a recombinant adeno-associated virus type 2 Reference Standard Material. Hum Gene Ther (2010) 1.51
Effective transplantation of photoreceptor precursor cells selected via cell surface antigen expression. Stem Cells (2011) 1.50
Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B. Blood (2010) 1.50
Retinal prosthetic strategy with the capacity to restore normal vision. Proc Natl Acad Sci U S A (2012) 1.50
Gene therapy with a promoter targeting both rods and cones rescues retinal degeneration caused by AIPL1 mutations. Gene Ther (2009) 1.48
Autozygome-guided exome sequencing in retinal dystrophy patients reveals pathogenetic mutations and novel candidate disease genes. Genome Res (2012) 1.47
Comprehensive molecular diagnosis of 179 Leber congenital amaurosis and juvenile retinitis pigmentosa patients by targeted next generation sequencing. J Med Genet (2013) 1.47
Long-term and age-dependent restoration of visual function in a mouse model of CNGB3-associated achromatopsia following gene therapy. Hum Mol Genet (2011) 1.47
Integration-deficient lentiviral vectors: a slow coming of age. Mol Ther (2009) 1.47
Restoration of cone vision in the CNGA3-/- mouse model of congenital complete lack of cone photoreceptor function. Mol Ther (2010) 1.46
Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. J Clin Invest (2015) 1.46
Transcriptome analyses of the human retina identify unprecedented transcript diversity and 3.5 Mb of novel transcribed sequence via significant alternative splicing and novel genes. BMC Genomics (2013) 1.46
Panel-based genetic diagnostic testing for inherited eye diseases is highly accurate and reproducible, and more sensitive for variant detection, than exome sequencing. Genet Med (2014) 1.46
Gene expression in the mouse eye: an online resource for genetics using 103 strains of mice. Mol Vis (2009) 1.44
Heparin binding induces conformational changes in Adeno-associated virus serotype 2. J Struct Biol (2008) 1.44
Optimized allotopic expression of the human mitochondrial ND4 prevents blindness in a rat model of mitochondrial dysfunction. Am J Hum Genet (2008) 1.43
Orderly recruitment of motor units under optical control in vivo. Nat Med (2010) 1.43
Viral and nonviral delivery systems for gene delivery. Adv Biomed Res (2012) 1.42
Which Leber congenital amaurosis patients are eligible for gene therapy trials? J AAPOS (2009) 1.42
The biochemical and structural basis for trans-to-cis isomerization of retinoids in the chemistry of vision. Trends Biochem Sci (2010) 1.42
Toward a clinical protocol for assessing rod, cone, and melanopsin contributions to the human pupil response. Invest Ophthalmol Vis Sci (2011) 1.41
Genome-editing Technologies for Gene and Cell Therapy. Mol Ther (2016) 1.41
The nonessentiality of essential genes in yeast provides therapeutic insights into a human disease. Genome Res (2016) 1.40
A novel adeno-associated viral variant for efficient and selective intravitreal transduction of rat Müller cells. PLoS One (2009) 1.40
RPE65: role in the visual cycle, human retinal disease, and gene therapy. Ophthalmic Genet (2009) 1.39
A partial structural and functional rescue of a retinitis pigmentosa model with compacted DNA nanoparticles. PLoS One (2009) 1.37
Safety and efficacy of subretinal readministration of a viral vector in large animals to treat congenital blindness. Sci Transl Med (2010) 1.35
Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease. Muscle Nerve (2009) 1.34
Functional and behavioral restoration of vision by gene therapy in the guanylate cyclase-1 (GC1) knockout mouse. PLoS One (2010) 1.33
Targeting photoreceptors via intravitreal delivery using novel, capsid-mutated AAV vectors. PLoS One (2013) 1.33
Donor and host photoreceptors engage in material transfer following transplantation of post-mitotic photoreceptor precursors. Nat Commun (2016) 1.33
Gene therapy restores vision in a canine model of childhood blindness. Nat Genet (2001) 7.88
Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle. Nat Genet (1998) 7.57
Idiopathic senile macular hole. Its early stages and pathogenesis. Arch Ophthalmol (1988) 5.74
Mutations in RPE65 cause autosomal recessive childhood-onset severe retinal dystrophy. Nat Genet (1997) 4.87
Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol Ther (2005) 4.74
Mutation of key residues of RPE65 abolishes its enzymatic role as isomerohydrolase in the visual cycle. Proc Natl Acad Sci U S A (2005) 4.67
RPE65 is the isomerohydrolase in the retinoid visual cycle. Proc Natl Acad Sci U S A (2005) 4.61
Rpe65 is the retinoid isomerase in bovine retinal pigment epithelium. Cell (2005) 4.51
Identifying photoreceptors in blind eyes caused by RPE65 mutations: Prerequisite for human gene therapy success. Proc Natl Acad Sci U S A (2005) 4.04
Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer. Mol Ther (2008) 3.28
Natural course of retinitis pigmentosa over a three-year interval. Am J Ophthalmol (1985) 2.98
Congenital stationary night blindness in the dog: common mutation in the RPE65 gene indicates founder effect. Mol Vis (1998) 2.74
Impairment of the transient pupillary light reflex in Rpe65(-/-) mice and humans with leber congenital amaurosis. Invest Ophthalmol Vis Sci (2004) 2.72
Clinical and molecular genetics of Leber's congenital amaurosis: a multicenter study of Italian patients. Invest Ophthalmol Vis Sci (2007) 2.69
Visual acuity as an outcome measure in clinical trials of retinal diseases. Ophthalmology (2007) 2.69
Early-onset severe rod-cone dystrophy in young children with RPE65 mutations. Invest Ophthalmol Vis Sci (2000) 2.67
Leber congenital amaurosis. Mol Genet Metab (1999) 2.52
Latency of the pupil light reflex: sample rate, stimulus intensity, and variation in normal subjects. Invest Ophthalmol Vis Sci (2003) 2.02
Eye movement recordings as an effectiveness indicator of gene therapy in RPE65-deficient canines: implications for the ocular motor system. Invest Ophthalmol Vis Sci (2006) 2.01
Test-retest reliability of the multifocal electroretinogram and humphrey visual fields in patients with retinitis pigmentosa. Doc Ophthalmol (2004) 1.94
The Briard dog: a new animal model of congenital stationary night blindness. Br J Ophthalmol (1989) 1.77
Pupillometric measures of retinal sensitivity in infants and adults with retinitis pigmentosa. Vision Res (1987) 1.39
Daily variation and effects of ambient light and circadian factors on the human light reflex. Methods Find Exp Clin Pharmacol (1992) 1.38
Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med (2011) 19.42
Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med (2006) 13.51
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology (2012) 11.91
Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med (2011) 11.01
A gene network regulating lysosomal biogenesis and function. Science (2009) 7.17
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet (2009) 6.71
Comparative analysis of RNA-Seq alignment algorithms and the RNA-Seq unified mapper (RUM). Bioinformatics (2011) 6.20
CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med (2007) 5.24
A high-resolution anatomical atlas of the transcriptome in the mouse embryo. PLoS Biol (2011) 4.84
In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature (2011) 4.81
Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol Ther (2005) 4.74
Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology (2006) 4.72
Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet (2011) 4.67
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood (2002) 4.60
Human chromosome 21 gene expression atlas in the mouse. Nature (2002) 4.36
Identifying photoreceptors in blind eyes caused by RPE65 mutations: Prerequisite for human gene therapy success. Proc Natl Acad Sci U S A (2005) 4.04
Candidate exome capture identifies mutation of SDCCAG8 as the cause of a retinal-renal ciliopathy. Nat Genet (2010) 3.99
Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther (2009) 3.93
G proteins and phototransduction. Annu Rev Physiol (2002) 3.74
AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood (2009) 3.65
The proteome of the mouse photoreceptor sensory cilium complex. Mol Cell Proteomics (2007) 3.53
Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest (2003) 3.52
Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood (2002) 3.45
Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer. Mol Ther (2008) 3.28
Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes. Mol Ther (2007) 3.26
Association between the SERPING1 gene and age-related macular degeneration: a two-stage case-control study. Lancet (2008) 3.21
Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol Ther (2011) 3.10
Massive light-driven translocation of transducin between the two major compartments of rod cells: a novel mechanism of light adaptation. Neuron (2002) 3.09
TTC21B contributes both causal and modifying alleles across the ciliopathy spectrum. Nat Genet (2011) 3.06
Physiological features of the S- and M-cone photoreceptors of wild-type mice from single-cell recordings. J Gen Physiol (2006) 3.00
MicroRNAs involved in molecular circuitries relevant for the Duchenne muscular dystrophy pathogenesis are controlled by the dystrophin/nNOS pathway. Cell Metab (2010) 2.99
Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis. Ann Neurol (2010) 2.96
Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med (2014) 2.92
AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med (2012) 2.87
Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology (2013) 2.82
Spontaneous activity of opsin apoprotein is a cause of Leber congenital amaurosis. Nat Genet (2003) 2.76
Impairment of the transient pupillary light reflex in Rpe65(-/-) mice and humans with leber congenital amaurosis. Invest Ophthalmol Vis Sci (2004) 2.72